Europe's biotech sector is entering a new era with 89 startups identified as reshaping medicine. The mapping by Sifted highlights the depth of innovation across the continent, spanning therapeutic areas from gene editing to AI-driven drug discovery.

Key hubs include Europe's traditional strongholds and emerging clusters, with investment flowing heavily into early-stage ventures. The report underscores the region's growing competitiveness in global biotech, driven by robust academic research and supportive policy frameworks.

Challenges remain, including regulatory fragmentation and talent retention, but the momentum suggests a transformative decade ahead. Venture capital activity has surged, reflecting confidence in the pipeline of novel therapies and platform technologies.